Видео ютуба по тегу Adrian Rawcliffe

Adaptimmune’s Adrian Rawcliffe On Changing Our Relationship With Cancer
Adaptimmune’s Adrian Rawcliffe On Changing Our Relationship With Cancer
JP Morgan Adrian Rawcliffe
JP Morgan Adrian Rawcliffe
Беседа с генеральным директором в 2026 году: Эд Роуклифф, генеральный директор Etiome.
Беседа с генеральным директором в 2026 году: Эд Роуклифф, генеральный директор Etiome.
The BioHub - The Avetix Podcast - S2 Ep29 - Adrian Rawcliffe
The BioHub - The Avetix Podcast - S2 Ep29 - Adrian Rawcliffe
T-Cells For The Win With Adaptimmune's Adrian Rawcliffe
T-Cells For The Win With Adaptimmune's Adrian Rawcliffe
Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune
Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune
Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy, Solid Tumors | E22
Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy, Solid Tumors | E22
What Makes The Cell Therapy Business Model Unique?
What Makes The Cell Therapy Business Model Unique?
CONVERGE Keynote: Defining and Delivering Value for the Future
CONVERGE Keynote: Defining and Delivering Value for the Future
Adaptimmune
Adaptimmune
Adaptimmune Therapeutics shares update on its late-stage clinical pipeline assets to treat cancer
Adaptimmune Therapeutics shares update on its late-stage clinical pipeline assets to treat cancer
Should Cell Therapy Companies Outsource Or Build Manufacturing Facilities?
Should Cell Therapy Companies Outsource Or Build Manufacturing Facilities?
ARM's 2021 Cell & Gene State of the Industry Briefing
ARM's 2021 Cell & Gene State of the Industry Briefing
Adaptimmune
Adaptimmune
Adaptimmune
Adaptimmune
Cell & Gene State of the Industry Briefing 2021
Cell & Gene State of the Industry Briefing 2021
Adaptimmune reports updated SURPASS data at ESMO 2021
Adaptimmune reports updated SURPASS data at ESMO 2021
What’s Next For Adaptimmune?
What’s Next For Adaptimmune?
Cell Therapies that Can Do a Solid for People with Cancer
Cell Therapies that Can Do a Solid for People with Cancer
Cell Therapy Milestones in 2023
Cell Therapy Milestones in 2023
Adaptimmune (ADAP|$451.6M) - 2025 Q1 Earnings Analysis
Adaptimmune (ADAP|$451.6M) - 2025 Q1 Earnings Analysis